Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application

References

• Mistry M, Parkin DM, Ahmad AS, et al. Cancer incidence in the United Kingdom: projections to the year 2030 epidemiology. Br J Cancer. 2011;105(11):1795–1803.
   PubMed Web of Science ®Google Scholar
• McKerrell T, Park N, Moreno T, Understanding Society Scientific Group, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015;10(8):1239–1245.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol. 2009;2(6):663–672.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–648.
   PubMed Web of Science ®Google Scholar
• Paczulla AM, Rothfelder K, Raffel S, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572(7768):254–259.
   PubMed Web of Science ®Google Scholar
• Farge T, Saland E, de Toni F, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716–735.
   PubMed Web of Science ®Google Scholar
• Li L, Osdal T, Ho Y, et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 2014;15(4):431–446.
   PubMed Web of Science ®Google Scholar
• Scheicher R, Hoelbl-Kovacic A, Bellutti F, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125(1):90–101.
   PubMed Web of Science ®Google Scholar
• Gao L, Yu S, Zhang X. Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages. Cell Biochem Biophys. 2014;70(1):273–277.
   PubMed Web of Science ®Google Scholar
• Carvajal LA, Neriah DB, Senecal A, et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018;10(436):eaao3003.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Daniel V, Sadeghi M, et al. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394(4):1098–1104.
   PubMed Web of Science ®Google Scholar
• Ye H, Adane B, Khan N, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19(1):23–37.
   PubMed Web of Science ®Google Scholar
• Despeaux M, Labat E, Gadelorge M, et al. Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia. 2011;25(11):1789–1793.
   PubMed Web of Science ®Google Scholar
• Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19(1):138–152.
   PubMed Web of Science ®Google Scholar
• Klco Jeffery M, Spencer David H, Miller Christopher A, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25(3):379–392.
   PubMed Web of Science ®Google Scholar
• Network CGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Eng J Med. 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Jung N, Dai B, Gentles AJ, et al. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat Commun. 2015;6:8489.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180–193.
   PubMed Web of Science ®Google Scholar
• Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011;43(5):470–475.
   PubMed Web of Science ®Google Scholar
• Ng AP, Alexander WS. Haematopoietic stem cells: past, present and future. Cell Death Discov. 2017;3(1):1700.
   Google Scholar
• Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol. 2013;98(6):648–657.
   PubMed Web of Science ®Google Scholar
• Smith L-L, Yeung J, Zeisig BB, et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell. 2011;8(6):649–662.
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7(3):299–313.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One. 2013;8(11):e78897.
   PubMed Web of Science ®Google Scholar
• Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA. 2006;103(31):11707–11712.
   PubMed Web of Science ®Google Scholar
• Gudas LJ, editor Retinoids induce stem cell differentiation via epigenetic changes. Semin Cell Dev Biol. 2013;24(10-12):701–705. doi:10.1016/j.semcdb.2013.08.002.
   Google Scholar
• Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5(7):738–743.
   PubMed Web of Science ®Google Scholar
• Boyd AL, Campbell CJV, Hopkins CI, et al. Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. J Exp Med. 2014;211(10):1925–1935.
   PubMed Web of Science ®Google Scholar
• Schepers K, Campbell TB, Passegué E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16(3):254–267.
   PubMed Web of Science ®Google Scholar
• Lagadinou Eleni D, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341.
   PubMed Web of Science ®Google Scholar
• Simsek T, Kocabas F, Zheng J, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7(3):380–390.
   PubMed Web of Science ®Google Scholar
• Takubo K, Nagamatsu G, Kobayashi Chiharu I, et al. Regulation of glycolysis by PDK functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell. 2013;12(1):49–61.
   PubMed Web of Science ®Google Scholar
• Bakker ST, Passegué E. Resilient and resourceful: Genome maintenance strategies in hematopoietic stem cells. Exp Hematol. 2013;41(11):915–923.
   PubMed Web of Science ®Google Scholar
• Fujisaki J, Wu J, Carlson AL, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature. 2011;474(7350):216–219.
   PubMed Web of Science ®Google Scholar
• Riether C, Schürch CM, Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22(2):187–198.
   PubMed Web of Science ®Google Scholar
• Greiner J, Ono Y, Hofmann S, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood, the Journal of the American Society of Hematology. 2012;120(6):1282–1289.
   Google Scholar
• Dickinson AM, Norden J, Li S, et al. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia. Front Immunol. 2017;8:496–496.
   PubMed Web of Science ®Google Scholar
• Schürch C, Riether C, Amrein MA, et al. Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. J Exp Med. 2013;210(3):605–621.
   PubMed Web of Science ®Google Scholar
• Naka K, Ohmura M, Hirao A. Regulation of the self-renewal ability of tissue stem cells by tumor-related genes. Cancer Biomark. 2007;3(4–5):193–201.
   PubMedGoogle Scholar
• Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12(4):446–451.
   PubMed Web of Science ®Google Scholar
• Naka K, Muraguchi T, Hoshii T, et al. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal. 2008;10(11):1883–1894.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–2264.
   PubMed Web of Science ®Google Scholar
• Hsu JI, Dayaram T, Tovy A, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23(5):700–713.e6.
   PubMed Web of Science ®Google Scholar
• Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 2008;270(1):1–9.
   PubMed Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J, et al. High levels of CD34 + CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a groupe Ouest-Est des leucemies aigues et maladies du sang (GOELAMS) study. Haematologica. 2011;96(12):1792–1798.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–1784.
   PubMed Web of Science ®Google Scholar
• Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31–42.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 2013;98(6):627–633.
   PubMed Web of Science ®Google Scholar
• Jan M, Chao MP, Cha AC, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA. 2011;108(12):5009–5014.
   PubMed Web of Science ®Google Scholar
• Arnone M, Konantz M, Hanns P, et al. Acute myeloid leukemia stem cells: the challenges of phenotypic heterogeneity. Cancers. 2020;12(12):3742.
   PubMed Web of Science ®Google Scholar
• Rouault-Pierre K, Hamilton A, Bonnet D. Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact. Expert Opin Biol Ther. 2016;16(4):463–476.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Malek SN, et al. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8(4):399–411.
   PubMed Web of Science ®Google Scholar
• Ji Q, Ding YH, Sun Y, et al. Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells. Oncotarget. 2016;7(40):65012–65023.
   PubMedGoogle Scholar
• de Jonge HJM, Woolthuis CM, Vos AZ, et al. Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia. 2011;25(12):1825–1833.
   PubMed Web of Science ®Google Scholar
• Velten L, Story BA, Hernández-Malmierca P, et al. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nat Commun. 2021;12(1):1366.
   PubMed Web of Science ®Google Scholar
• Pabst C, Bergeron A, Lavallée V-P, et al. GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 2016;127(16):2018–2027.
   PubMed Web of Science ®Google Scholar
• Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–333.
   PubMed Web of Science ®Google Scholar
• Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179–1181.
   PubMed Web of Science ®Google Scholar
• Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487.
   PubMed Web of Science ®Google Scholar
• Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int. 2016;113(18):317–322.
   PubMed Web of Science ®Google Scholar
• Flynn CM, Kaufman DS. Donor cell leukemia: insight into cancer stem cells and the stem cell niche. Blood. 2007;109(7):2688–2692.
   PubMed Web of Science ®Google Scholar
• Frick M, Chan W, Arends CM, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37(5):375–385.
   PubMed Web of Science ®Google Scholar
• Tal Shahar G, Noa C-I, Yoni M, et al. Donor cell leukemia: reappearance of gene mutations in donor cells - more than an incidental phenomenon? Haematologica. 2020;105(12):2861–2863.
   PubMed Web of Science ®Google Scholar
• Laverdière I, Boileau M, Neumann AL, et al. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J. 2018;8(6):52.
   PubMedGoogle Scholar
• Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114(25):5126–5135.
   PubMed Web of Science ®Google Scholar
• Parkin B, Londoño-Joshi A, Kang Q, et al. Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. J Clin Invest. 2017;127(9):3484–3495.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Nacheva EP, Grace CD, Brazma D, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol. 2013;161(4):541–550.
   PubMed Web of Science ®Google Scholar
• Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11(1):5327.
   PubMed Web of Science ®Google Scholar
• Li S, Garrett-Bakelman FE, Chung SS, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22(7):792–799.
   PubMed Web of Science ®Google Scholar